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Summary
Since their discovery in 1915, bacteriophages have been routinely used within
Eastern Europe to treat a variety of bacterial infections. Although initially
ignored by the West due to the success of antibiotics, increasing levels and
diversity of antibiotic resistance is driving a renaissance for bacteriophage-
derived therapy, which is in part due to the highly specific nature of
bacteriophages as well as their relative abundance. This review focuses on the
bacteriophages and derived lysins of relevant Gram-positive spore formers
within the Bacillus cereus group and Clostridium genus that could have
applications within the medical, food and environmental sectors.
Bacteriophages and their derived lysins
Bacteriophages are believed to be the most abundant bio-
logical entities on the planet (estimated at 1031 plaque
forming units) and are present in nearly every environ-
ment. They are well known to play important roles in the
control of bacterial populations and bacterial evolution
(Stern and Sorek 2011). During the early part of the 20th
century, bacteriophages were first used as a therapeutic
agent under a variety of different commercial names
(Bacte-intesti-phages, Bacte-pyo-phages, Bacte-coli-phages,
Bacte-rhino-phages and Bacte-staphy-phage; Abedon et al.
2011). Bacteriophage preparations were also successfully
deployed to treat wounded Red Army soldiers during the
Soviet invasion of Finland in 1938 (Chanishvili et al.
2001). With the discovery and subsequent success of anti-
biotics, bacteriophage research and clinical use has been
primarily confined to the former Soviet Union due to
concerns over safety and efficacy (Hanlon 2007).
Although renewed Western interest has stimulated the
commercialization of some phage cocktails (Listex P100,
SalmoFresh, ListShield etc.), these have been confined to
the food industry where bacterial contamination is an
increasing burden ( _Zaczek et al. 2015). The success of
phage-based products within the food industry is not
only driven by their relative ease of application ( _Zaczek
et al. 2015) but also due to negative public perception of
chemically treated food and positive perception of phages
(Naanwaab et al. 2014) together with increasing levels of
legislation restricting the use of antibiotics (Seal 2013).
The improper prescription or nonprescription sale of
antibiotics in some countries, and also poor patient com-
pliance, has contributed to the rapid spread of multidrug
resistance in human pathogens. Phages and their derived
endolysins offer a number of advantages over conven-
tional antibiotic therapy, ranging from their high degree
of specificity, to relative abundance in the environment
which should allow for any developed resistance to be
overcome, simply by changing the phage.
Although the simplest explanation of bacteriophage rep-
lication focuses on two lifecycles, the lytic and lysogenic
cycles (Fig. 1), there are multiple variations on these cycles
including pseudolysogeny (continual infection) and
chronic infection (progeny release through budding) which
take place particularly when hosts lack nutrients (Golais
et al. 2013). Endolysins are produced at the end of the lytic
phage lifecycle, accumulated within the host cell cytoplasm
until they are activated releasing progeny phage by the
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cleavage of peptidoglycan bonds (Fischetti 2010). Endoly-
sins possess a globular or modular structure (Walmagh
et al. 2013). Endolysins of Gram-negative bacteria are pri-
marily globular in structure possessing only a catalytic
domain (Callewaert et al. 2011), while lysins of Gram-posi-
tive bacteria are usually 25–40 kDa large (Fischetti 2010),
modular in structure and exhibit variety in their architec-
ture that goes beyond the classical two domain structure of
endolysins (Yuan et al. 2012a).
The highly conservative N-terminal domain has cata-
lytic activity and is responsible for enzymatic function.
Endolysins may demonstrate several types of enzymatic
activity, and therefore may be divided into five different
classes according to the identity of their N-terminal
domain: 1) N-acetylmuramidases (lysozymes), 2) endo-
b-N-acetylglucosaminidases, 3) lytic trans-glycosylases, 4)
endopeptidases, and 5) N-acetylmuramyl-L-Ala-amidases.
Classes 1–3 cleave the sugar moieties; class 4 cleaves pep-
tide moieties, while class 5 cleaves peptide bonds between
these two moieties. The most populated classes include
amidases and muramidases; all endolysins, except for
transglycolases, are hydrolases (Schmelcher et al. 2012).
The C-terminal domain is capable of specifically recog-
nizing ligands (usually carbohydrate ligands) within the
bacterial wall, and is responsible for tethering the endoly-
sin molecule to peptidoglycan. The number of binding
domains varies between endolysins (Yuan et al. 2012a).
The affinity is so strong that it may be compared to anti-
gen-antibody binding (Loessner et al. 2002).
The importance of Bacillus and Clostridium spore
formers
Members of both the Bacillus cereus group and Clostridium
genus possess the ability to form endospores upon
starvation (Leggett et al. 2012). This allows the bacterium
to remain dormant for long periods of time. Among the
most notable feature of bacterial endospores is the
increased level of resistance to decontamination efforts
ranging from biocides (Leggett et al. 2015) to ionizing
radiation (Moeller et al. 2014; Setlow et al. 2014) which
present challenges to those seeking to remediate spore
contamination.
The Bacillus cereus group is a highly homogenous sub-
division of the Bacillus genus, and its primary members
comprise of B. cereus, Bacillus anthracis and Bacillus thur-
ingiensis. Bacillus mycoides, Bacillus pseudomycoides and
Bacillus weihenstephanensis are minor members of this
group (Priest et al. 2004; Rasko et al. 2005). Although
most members of this group are considered to be
nonpathogenic (Ceuppens et al. 2013), B. cereus and
B. anthracis are known to cause serious human disease.
Bacillus anthracis is perhaps the most widely known,
causing three forms of anthrax, cutaneous, gastrointesti-
nal and inhalational. Cutaneous anthrax is the most com-
monly exhibited form in humans resulting from close
contact with contaminated environments and contami-
nated animal products (Doganay and Metan 2009), while
gastrointestinal and inhalational anthrax are considerably
rarer but often more severe. Bacillus cereus is a common
soil dwelling bacterium, which easily spreads to foodstuffs
and exhibits two types of disease in humans as the result
of toxin production. The two forms of B. cereus poison-
ing are diarrhoeal, the result of bacterial growth within
the small intestine and the emetic form which results
from growth on foodstuffs (Granum and Lund 1997).
Both forms of B. cereus poisoning have been implicated
in 235 suspected or confirmed outbreaks between 1998
and 2008 (Bennett et al. 2013). The high degree of
genetic similarity between the major members of this
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Figure 1 Simplified schematic representation
of bacteriophage lifecycle. Adapted from
(Sulakvelidze et al. 2001).
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group complicates diagnosis with many PCR-based assays
unable to consistently distinguish between them (Rasko
et al. 2005). Indeed, plasmid-associated genes encoding
virulence factors such as toxin production are also shared
between strain as is the case with B. anthracis and
B. cereus G9241 (Hoffmaster et al. 2004).
The Clostridium genus contains approx. 100 species
which are spore forming obligate anaerobes. This genus
contains species which are useful to industrial applica-
tions, Clostridium thermocellum which is used in bioetha-
nol production and Clostridium beijerinckii involved in
biohydrogen production (Roberts et al. 2010; Seelert
et al. 2015) as well as human pathogens Clostridium diffi-
cile, Clostridium perfringens (Seal 2013; Hargreaves and
Clokie 2014). Despite existing as a minor component of
the gut commensal microflora, Cl. difficile has emerged as
an important source of healthcare-associated infections
within the developed world (Hargreaves and Clokie 2014)
with an estimated economic impact of $48 billion in
excess medical costs within the USA alone (Dubberke
and Olsen 2012). Clostridium perfringens and Clostridium
botulinum are both commonly found contaminants of
food products that are able to cause gastrointestinal dis-
eases resulting from toxin production, usually type A
toxin (Lund and Peck 2013; Seal 2013), with Cl. perfrin-
gens being confirmed to be or suspected to being impli-
cated in 536 foodborne disease outbreaks between 1998
and 2008 in the USA (Bennett et al. 2013).
Bacteriophages of Bacillus and Clostridium
Although virulent phages have been isolated and charac-
terized against multiple Bacillus species (Table 1), Cl. dif-
ficile phages appear to be wholly temperate in nature
(Table 2) and when induced show instability and a ten-
dency to reintegrate into the host genome following the
removal of inducers such as mitomycin C (Meessen-
Pinard et al. 2012).
The use of the lytic c bacteriophage against B. anthracis
has long been established as a diagnostic method for
anthrax due to its high specificity (≥95%) (Abshire et al.
2005). However, the application of phages to therapy
requires a wider host range and maintenance of activity.
The B. cereus Bc431v3 phage, a member of the Myoviri-
dae, was able to cause different levels of lysis within mul-
tiple strains of B. cereus, B. anthracis, B. licheniformis
and B. weihenstephanensis based upon plaque formation
(El-Arabi et al. 2013).
The presence of Tectiviridae within the B. cereus group
is at a lower prevalence (3% from 2000 B. cereus group
isolates) compared to members of the Caudovirale (Gillis
and Mahillon 2014). Analysis of the host range of phages
from the Tectiviridae showed that the host range was
divided into two clusters, with phages that infect
B. anthracis in one cluster and those isolated from other
B. cereus group members in the other and that within
these two groups, a greater DNA diversity exists than pre-
viously thought (Gillis and Mahillon 2014).
The majority of the published literature focuses on
Cl. difficile phages due to its impact on human health
and as such has been reviewed in greater detail elsewhere
(Hargreaves and Clokie 2014). These phages are primarily
members of the Myoviridae with some members of the
Siphoviridae also present (Nale et al. 2012; Sekulovic
et al. 2014). The study by Sekulovic et al. (2014) also
suggested that Siphoviradae phages isolated from human
Cl. difficile isolates possessed a wider host rage than their
animal counterparts.
Clostridium perfringens phage /3626 was shown to be
lytic against 11 strains of 51 Cl. perfringens strains that
were assessed. This phage has also shown the presence of
a sporulation associated sigma factor within ORF32, it
was hypothesized that this may have an effect on the
sporulation of Cl. perfringens, as the curing of a lysogenic
strain resulted in decreased heat resistance, sporulation
efficacy and potentially the expression of the Cpe entero-
toxin (Zimmer et al. 2002).
Although phages isolated from Cl. difficile are lysogenic
in nature, some phages isolated from Cl. perfringens exhi-
bit lytic tendencies (Volozhantsev et al. 2012). The
ΦCPV1 phage is a lytic member of the Podoviridae is
distantly related to Φ29-like viruses when compared
using protein sequences. However, ΦCPV1 would likely
be classified to this group based on the number of pro-
tein sequences and the presence of a phage–encoded
DNA polymerase. Sequence analysis also revealed the
presence of two genes that encode for a N-acetylmura-
moyl L-alanine amidase and a lysozyme-endopeptidase.
These sequences shared no homology to other known ho-
lins (Volozhantsev et al. 2012).
Comparative genomic analysis between four Cl. per-
fringens phages (ΦCP9O, ΦCP13O, ΦCP26F and
ΦCP34O) showed significant genomic diversity between
phages particularly within endolysin regions that could be
split into one of two distinct genotypes (Oakley et al.
2011).
Endolysins of Bacillus and Clostridium
Produced during the late stages of phage infection, endol-
ysins are designed to attack the peptidoglycan that holds
the bacterial cell together, to release phage progeny. The
cleavage site is within or between the sugar or peptide
moieties of peptidoglycan (Elbreki et al. 2014). Summa-
ries on phage-derived endolysins for Bacillus and Clostrid-
ium can be found in Tables 3 and 4 respectively.
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LysB4, isolated from B. cereus phage B4, differs from
many of the other B. cereus phage-derived endolysins due
to its endopeptidase (cleaving the bonds between L-Ala
and D-Glu), rather than amidase activity (Son et al.
2012) although this lysin is not unique in possessing a
nonamidase mechanism of action. LysB4 also requires the
presence of zinc or manganese ions to maintain proper
activity (Son et al. 2012). This endolysin possessed a wide
range of activity against Gram-positive organisms
(including B. subtilis and Listeria monocytogenes strains)
as well as activity against some Gram-negative pathogens
including Pseudomonas aeruginosa and Salmonella ty-
phimurium that had been pretreated with EDTA (Son
et al. 2012). The same B. cereus strain was the host for
the phage BPS13. Isolation and subsequent analysis using
BLASTP software have shown that endolysin LysBPS13
belongs to a class of N-acetylmuramyl-L-Ala-amidases,
which generates free N-acetylmuramic acid from murein
in treated bacterial cells. LysBPS13 is built of a peptido-
glycan recognition protein domain with catalytic proper-
ties and a zinc-binding capability resulting from a
conserved motif of three amino acid moieties, His29,
His129 and Cys137. However, the C/N terminus of this
endolysin is still to be fully characterized (Park et al.
2012). LysBPS13 is also characterized by a relatively
broad spectrum of activity, including several strains of
B. cereus, B. thuringiensis, B. licheniformis, B. megaterium
and Bacillus pumilus (Park et al. 2012). LysBPS13 is ther-
mally stable and thermal stability can be further enhanced
in combination with 30% (v/v) glycerol. Only a few end-
olysins with high temperature resistance have been
reported to date (Lavigne et al. 2004).
The PlyG endolysin, encoded by the B. anthracis
c phage, has a narrow spectrum of activity that
encompasses only the anthrax bacterium, therefore testing
the resistance of a strain to this particular lysin is a sim-
ple and quick method for the identification of this patho-
gen. Yang et al. (2012) demonstrated that different PlyG
domains are responsible for binding to vegetative cells
and spores. A spore binding domain was identified, con-
sisting of 60 amino acids, with binding sites most proba-
bly located within the exosporium of a spore. However,
the tests led to only a moderate reduction (approx.
1–2 log10) in spore numbers following a 30-min exposure
to endolysin, even in the presence of L-alanine as the ger-
mination inducer. When the N-terminal structure of
PlyG was modified (via point mutations), a histidine resi-
due at position 29 and a glutamic acid residue at position
90 were required for catalytic activity (Kikkawa et al.
2008). In addition, the binding domain of PlyG was stud-
ied, showing that elimination of its central part com-
pletely deprives the enzyme of its lytic activity, suggesting
that both domains are equally important for the enzyme
to function properly (Kikkawa et al. 2008). The thermal
stability of PlyG has been investigated and it has been
shown that PlyG maintains ≥80% relative lytic activity at
temperatures up to 60°C in the presence of a tris(2-carb-
oxyethyl)phosphaline (TCEP) reducing agent after a
10 min exposure time. However, without the TCEP, this
activity dropped to approx. 40% at 50°C. The endolysin
exhibited a varied half-life depending on the storage tem-
perature. At 50°C this was approx. 35 h while at 55°C
this decreased to 35 h (Heselpoth et al. 2015). PlyG for
therapeutic has recently been patented and demonstrates
increased levels of survival in B. anthracis infected mice
that were subsequently treated with PlyG (Fischetti et al.
2013). However, the requirement to induce spore germi-
nation prior to the addition of PlyG could limit its
Table 1 Summary of the bacteriophages of the Bacillus group
Bacteriophage Morphology Host Genome size (kbp)* GC% References
B4 Myoviridae Bacillus cereus 1626 3771 Lee et al. (2013)
BPS13 Myoviridae B. cereus 1583 3875 Shin et al. (2014)
BPS10C Myoviridae B. cereus 1596 3874 Shin et al. (2014)
12826 Not classified B. cereus –† –† Loessner et al. (1997)
Bc431v3 Myoviridae B. cereus 1586 3998 El-Arabi et al. (2013)
PBC1 Siphoviridae B. cereus 412 4168 Kong et al. (2012)
BCP78 Siphoviridae B. cereus 1562 3986 Lee et al. (2012)
Bastille Myoviridae B. cereus 1270 n.d Loessner et al. (1997)
c Siphoviridae Bacillus anthracis 373 3522 Fouts et al. (2006)
Fah Siphoviridae B. anthracis 380 3494 Minakhin et al. (2005)
Cherry Siphoviridae B. anthracis 366 –† Oey et al. (2009)
AP50 Tectiviridae B. anthracis 144 3865 Sozhamannan et al. (2008)
vB_BanS-Tsamsa Siphoviridae B. anthracis 1689 34 Ganz et al. (2014)
BtCS33 Siphoviridae Bacillus thuringiensis 420 3522 Yuan et al. (2012b)
*Genome size has been rounded to the nearest 100 bp.
†No data available. Bacteriophage structure has been reviewed in greater detail elsewhere (Ackermann 2012).
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potential application in human therapy. The PlyB endoly-
sin (derived from phage Bcpl) has a different mechanism
of action compared to that of PlyG, cleaving the bond
between the N-acetylmuramic acid and N-acetylglucos-
amine. This lysin could also potentially be applied as a
human therapeutic for those with an active B. anthracis
infection as it has been shown that administration of
25 lmol l1 of the endolysin resulted in the complete
lysis of an exponentially growing culture of B. anthracis
ATCC 4342 (Porter et al. 2007).
PlyBt33 is classified as an N-acetylmuramyl-L-Ala ami-
dase and was obtained from bacteriophage BtCS33, pos-
sessing lytic activity against B. thuringiensis kurstaki strain
CS-33. It showed high lytic activity against B. cereus
group members, including B. cereus and B. anthracis.
Specific activity was also observed in B. pumilus and
B. subtilis strains, whereas the degree of lysis achieved in
B. thuringiensis was quite low (Yuan et al. 2012a). This
particular endolysin is also separated from other endoly-
sins by relatively high thermal stability.
The CD27L lysin derived from the Cl. difficile ΦCD27
phage has been shown to possess zinc dependent N-ace-
tylmuramoyl-L-alanine amidase activity against multiple
Cl. difficile strains but possessed no activity against other
Clostridium species (Mayer et al. 2008). A follow up
study by the same group showed that lytic activity
resided in the N-terminal domain (amino acids 1–179)
and that truncation of the endolysin could increase activity
Table 2 Summary of the bacteriophages of the Clostridium group
Bacteriophage Morphology Host Genome size (kbp)* GC% References
ΦC2 Myoviridae Clostridium difficile 565 287 Goh et al. (2007)
ΦC5 Myoviridae Cl. difficile 459 –† Goh et al. (2005)
ΦC6 Siphoviridae Cl. difficile 363 –†
ΦC8 Myoviridae Cl. difficile 545 –†
ΦCD27 Myoviridae Cl. difficile 509 294 Mayer et al. (2008)
ΦMMP01 Myoviridae Cl. difficile –† –† Meessen-Pinard et al. (2012)
ΦMMP02 Myoviridae Cl. difficile 484 296
ΦMMP03 Myoviridae Cl. difficile –† –†
ΦMMP04 Myoviridae Cl. difficile 317 303
ΦCP24R Podoviridae Clostridium perfringens 189 278 Morales et al. (2012)
ΦCPV1 Podoviridae Cl. perfringens 167 305 Volozhantsev et al. (2011)
Φ3626 Siphoviridae Cl. perfringens 335 284 Zimmer et al. (2002)
ΦCPV4 Podoviridae Cl. perfringens 180 –†
ΦZP2 Podoviridae Cl. perfringens 181 –† Volozhantsev et al. (2012)
ΦCP7R Podoviridae Cl. perfringens 184 –†
Φ8701-B1 Siphoviridae Cl. sporogenes 476 354 Mayer et al. (2012)
ΦCTP1 Siphoviridae Cl. tyrobutyricum 519 –† Mayer et al. (2010)
*Estimated and rounded to the nearest 100 bp.
†No data available. Bacteriophage structure has been reviewed in greater detail elsewhere (Ackermann 2012).
Table 3 Summary of the enzymatic activity and physical characteristics of bacteriophage-derived endolysisns of members of the Bacillus group
Endolysin Bacteriophage Enzymatic activity Mass (kDa) Length (aa) References
LysB4 B4 Endopeptidase 28 260 Son et al. (2012)
LysBPS13 BPS13 Amidase 37 277 Park et al. (2012)
Ply12 12826 Amidase 277 257 Loessner et al. (1997)
Ply21 TP21 Amidase 295 263
PlyBa Bastille Glycosidase 411 364
PlyG c Amidase 262 233 Kikkawa et al. (2007, 2008), Yang et al. (2012)
PlyB BcpI Muramidase –* n.d. Porter et al. (2007)
Phage AP50c lysine AP50c Amidase 277 252 Sozhamannan et al. (2008)
PlyBT33 BTCS33 Amidase 33 272 Yuan et al. (2012a)
PlyPH –* Amidase –* n.d Yoong et al. (2006)
PlyL Ba02 Amidase –* 263 Low et al. (2005)
AmiBA2446 –* Amidase c. 24 245 Mehta et al. (2013)
PlyBt33 BtCS33 Amidase 33 –* Yuan et al. (2012a)
*No data available.
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and host range with the maintenance of some degree of
target specificity (Mayer et al. 2011). The C-terminal
domain was unable to produce specific lysis (Mayer et al.
2011). The combination of the CD27L –terminal with the
CS74L N-terminal domain resulted in a decrease in the
activity against Clostridium tyrobutyricum while chimeric
CS74L was still unable to target CD27L sensitive bacteria
(Mayer et al. 2012).
The Psm-his-derived endolysin isolated from C. per-
fringens showed specific activity and was unable to lyse
C. difficile or Clostridium histolyticum (Nariya et al.
2011). A great difference was observed between the vari-
ous toxin types of C. perfringens with toxin type E being
the most resistant when assessed using mid log phase cul-
tures (22 400 U ml1) compared to toxin type C
(8000 U ml1).
Application of Bacillus and Clostridium-derived
phages and endolysins
There is a pressing need to differentiate between the
members of B. cereus group, particularly for the identifi-
cation of B. anthracis. As stated previously, the high
degree of genetic similarity between the primary members
of this group makes differentiation difficult and has been
demonstrated for the identification of B. anthracis, where
35 PCR-based assays were evaluated and only four shown
to be 100% specific. Of these four assays, three targeted a
prophage associated region within the chromosome
(Agren et al. 2013).
The use of c phage for the confirmation and diagnosis
of B. anthracis is well established due to the high specific-
ity for B. anthracis, while most B. cereus and B. thuringi-
ensis strains are resistant to c phage infection (Abshire
et al. 2005). The use of bioluminescence integrated into
both c and Wb phages has been developed for clinical
diagnostics (Schofield et al. 2013) to reduce the time
taken to detect B. anthracis. Schofield et al. (2013) dem-
onstrated that a bioluminescent reporter phage can detect
B. anthracis within 5 h in clinically relevant samples and
also provide information on the antibiotic susceptibility
profile of that organism, fulfilling a need for rapid diag-
nostic and treatment assessment in the event of an emer-
gency.
Phage-based diagnostics are not only limited to using
replicating phage particles. The use of phage endolysin-
derived cell binding domains (CBD) combined with para-
magnetic beads have been shown to be able to detect
L. monocytogenes that was both in suspension and immo-
bilized on contaminated foodstuffs (Kretzer et al. 2007).
The same study also demonstrated that the procedure
could be expanded to include other common contami-
nants of foodstuffs (B. cereus and Cl. perfringens) using
CBDs that were derived from specific endolysins.
Although limited information exists on the efficacy of
phages and their derived endolysins in in vivo testing
these studies are concerned with nonspore forming
organisms such as Staphylococcus aureus (Yang et al.
2014; Schmelcher et al. 2015). Endolysins have been
shown to successfully treat infected mice that were chal-
lenged with an intraperitoneal dose of B. cereus RSVF1
(Schuch et al. 2002). This study showed that the adminis-
tration of 50 U of PlyG within 15 min of infection
resulted in a 684% full recovery rate and the remainder
of the mice (6 of 19) survived up to 21 h. Increased PlyG
admission resulted in a higher recovery rate (769%),
while control animals (PBS treated) died within 24 h
(Schuch et al. 2002). Another study showed a 40% com-
plete survival of mice infected with an intraperitoneal
injection of B. cereus RSVF1 that were subsequently trea-
ted with a second endolysin PlyPH (Yoong et al. 2006).
Use of an experimental colon model of Cl. difficile infec-
tion has shown that although numbers of vegetative cells
can be reduced through the application of a single bacte-
riophage (ΦCD27) compared to an untreated control (in
66% of cases), the number containing the ΦCD27 pro-
phage (t = 35 days) was approx. 90% by the conclusion
of the experiment (Meader et al. 2013). This study also
suggested that infection and integration by ΦCD27 pre-
cludes the production of Cl. difficile associated toxins. A
Table 4 Summary of the enzymatic activity and physical characteristics of bacteriophage-derived endolysins of members of the Clostridium
group
Endolysin Bacteriophage Enzymatic activity Mass (kDa) Length (aa) References
CD27L ΦCD27 Amidase 32 270 Mayer et al. (2012, 2008)
CS74L ATCC 8074-B1 Amidase 311 –*
Psm-his ΦSM101 Muramidase 40 –* Nariya et al. (2011)
Ctp11 ΦCTP1 –* 33 274 Mayer et al. (2010)
Ct –* 24 197
Ply3626 Φ3626 Amidase 388 347 Zimmer et al. (2002)
CP25L –* Amidase 45 –* Gervasi et al. (2014)
*No data available.
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summary of Bacillus and Clostridium phages and endoly-
sins that have been evaluated under nonlaboratory condi-
tions can be found in Table 5.
The application of a multivalent phage cocktail (INT-
401) to broiler chickens, showed that mortality due to
Cl. perfringens-induced necrotic enteritis was reduced by
92% when the cocktail was administered orally (Miller
et al. 2010). A second study performed by the same
group also demonstrated that the cocktail could be suc-
cessfully administered via their drinking water or feed.
The expression of a Cl. perfringens endolysin (CP25L)
within a probiotic Lactobacillus lactis strain presents an
interesting alternative to the use of a replicating phage
cocktail (Seal 2013; Gervasi et al. 2014) and has demon-
strated activity against multiple Cl. perfringens strains
in vitro and a limited level of cross species activity against
a strain of B. cereus and B. subtilis (Gervasi et al. 2014).
Challenges facing the implementation of
bacteriophage or derived endolysins for use
against bacterial spore formers
The ability of both Bacillus and Clostridium members to
form endospores represents a challenge to both chemical
based decontamination efforts and antibiotic therapy. To
force spores to germinate, additional compounds are
often added to mimic conditions that would be present
within a susceptible host (e.g. L-alanine and inosine in
the case of Bacillus or bile salts for Cl. difficile). It has
been suggested that B. anthracis endolysin PlyG can bind
to the spore itself, and a 1 log10 reduction was observed
after 1 h in combination with L-alanine (Yang et al.
2012). The ability of B. anthracis and B. thuringiensis to
germinate within a soil matrix has shown that triggering
germination can result in a decrease in total number of
viable cells over an extended period of time (Bishop
2014).
The presence of other bacterial structures has also been
suggested to play a role in resisting bacteriophage infec-
tion. The capsule layer produced by B. anthracis contain-
ing both pXO1 and pXO2 plasmids in the presence of
carbon dioxide has been shown to inhibit lytic infection
by B. anthracis-specific phages (Negus et al. 2013).
Although not demonstrated this principle should also
apply to other Clostridium species, in particular Cl. diffi-
cile due to the presence of capsular polysaccharides (Reid
et al. 2012).
Bacteriophages are well known to the horizontal trans-
fer of genes between bacterial species and have been
shown to be able to move antibiotic resistance markers in
Cl. difficile (Goh et al. 2013). In general lytic phages are
regarded as more appropriate for use in therapy as tem-
perate phages have been shown to possess a lower killing
potential and can spread genes which enhance bacterial
virulence (Kropinski 2006; Fard et al. 2011; Loc-Carrillo
and Abedon 2011). Therefore, the complete characteriza-
tion of phage genomes prior to inclusion in therapeutics
is vital.
To protect themselves from predation, bacterial popu-
lations have developed a number of different mechanisms
by which they can become resistant to infection by bacte-
riophages, such as exclusion or the Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR) Cas sys-
tem (Abedon 2012; Barrangou and van der Oost 2015;
Goldfarb et al. 2015). In brief the CRISPR/Cas system
can immunize bacterial cells against foreign nucleic acids
as well as providing some degree of lasting immunity.
For initial immunization, foreign DNA is cleaved by a
Cas complex of proteins producing a novel spacer unit,
which is subsequently incorporated into a CRISPR array.
Table 5 Summary of nonbroth or agar-based studies using Clostridium and Bacillus bacteriophages or lysins
Species Endolysin\Phage In vitro\vivo Results References
Bacillus PlyG In vivo- mouse i.p. injection • 684% of mice fully recovered (>72 h)
• 100% survival (≤21 h)
Schuch et al. (2002)
PlyPH • 40% survival of mice (>35 h) Yoong et al. (2006)
Clostridium ΦCD27 In vitro human colon model • Reduction in Clostridium difficile
vegetative and spore numbers
• Reduction in toxin production
Meader et al. (2013)
CD140 In vivo hamster All hamsters succumbed to Cl. difficile infection
within 3 days of the second challenge
Ramesh et al. (1999)
INT-401 cocktail In vivo chicken • Chickens challenged with Clostridium
perfringens
• Challenged control animals showed
64% mortality due to necrotic enteritis
• Mortality decreased to 0% when phage
administered in water and <1% when
administered in feed
Miller et al. (2010)
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Upon repeat exposure this CRISPR array is transcribed
and processed into individual CRISPR RNAs (crRNAs).
These crRNAs are then used to guide a Cas complex to
target and inactivate the foreign nucleic acid. A more com-
prehensive review of the CRISPR/Cas system has been pro-
duced by Horvath and Barrangou (2010). Although the
development of resistance will play an important role in
determining the success of any bacteriophage based ther-
apy, the mechanisms have been reviewed in much greater
detail elsewhere (Westra et al. 2012).
The development of endolysin resistance could be of
some concern should they be used in a clinical setting.
However, endolysins are targeted towards highly con-
served features of the bacterial cell surface and the devel-
opment of such resistance would require a fundamental
alteration of peptidoglycan architecture (Elbreki et al.
2014). Although attempts have been made to develop this
type of resistance in vitro (Briers et al. 2014) no lysin
resistant bacteria have been isolated to date (Herpers
2015). This hurdle could also potentially be overcome
through the creation of chimeric endolysins derived from
different parental phages and has been demonstrated in
Staph. aureus (Mao et al. 2013).
Although a recent study suggested that consumers
would be willing to pay extra for fresh produce that had
been treated with bacteriophage (Naanwaab et al. 2014),
public reaction to bacteriophage-derived products pre-
sented as a therapeutic option either separately or in
combination with antibiotics is unknown.
To produce successful phage based therapeutics a num-
ber of criteria must be met. These include not only the
ability to infect a range of strains as well as the ability to
reduce the overall level of infection (Hanlon 2007), but
also compliance, both patient and regulatory. The satis-
faction of regulatory requirements for topically applied
phage products should be relatively simple to attain (i.e.
low bacterial content, absence of Staph. aureus, Ps. aeru-
ginosa and Escherichia coli). However, for nontopical
applications (e.g. systemic applications), regulatory
requirements would be more stringent, particularly endo-
toxin content. To meet such challenges, current legisla-
tion would need to be revised in which acceptable criteria
for phage based therapeutics would be established
(Verbeken et al. 2014) as well as increasing research into
effective endotoxin removal without the use of extreme
pH or temperature.
Unlike antibiotics, phages and their derived lysins will
initiate an immune response in the patient, enhancing
clearance from the body and lowering their efficacy
(Elbreki et al. 2014). To reduce this response, prepara-
tions could be combined with additional excipients
such as polyethylene glycol that could mask the phage or
endolysin from the immune system (Fenton et al. 2010).
Following the successful lysis of the target bacterium, the
accumulation of proinflammatory cellular debris (such as
lipopolysaccharide) could also result in an escalation of
any immune response produced.
Conclusions and outlook
Bacterial spore formers represent a unique challenge to
those seeking to adapt whole bacteriophages and their
derived endolysins due to their ability to survive decon-
tamination efforts and remain viable. Currently much of
the available literature focuses on the primary isolation
and characterization of such entities rather than the
development of practical applications. Although derived
from virulent bacteriophage, endolysins possess a number
of advantages over their parent phages such as a wider
host range (Son et al. 2012) and ability to interact with
spores as well as vegetative cells (Yang et al. 2012). The
ability to produce such enzymes in recombinant forms
may allow for large scale, cost effective production. How-
ever, a number of secondary issues need to be addressed
to produce effective, safe therapies, particularly the evalu-
ation of testing beyond laboratory conditions.
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